Navigation Links
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
Date:11/15/2011

a of PL-3994 and a new peptide drug candidate for sexual dysfunction.

CASH POSITIONPalatin's cash and cash equivalents were $14.9 million as of September 30, 2011, compared to $18.9 million at June 30, 2011, with current liabilities of $1.7 million as of September 30, 2011 compared to $2.8 million as of June 30, 2011.

Palatin believes, based on its current operating plan, that its cash and cash equivalents will be sufficient to fund its operations through at least calendar year 2012.

CONFERENCE CALL / WEBCAST Palatin will host a conference call and webcast on November 15, 2011 at 11:00 a.m. Eastern Time to discuss the results of operations in greater detail and an update on corporate developments.  Individuals interested in listening to the conference call live can dial 1-888-256-1007 (domestic) or 1-913-312-1466 (international), pass code 3249586. The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com. A telephone and webcast replay will be available approximately one hour after the completion of the call. To access the telephone replay, dial 1-888-203-1112 (domestic) or 1-719-457-0820 (international), pass code 3249586.  The webcast and telephone replay will be available through November 22, 2011.

About Palatin Technologies, Inc. Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.  Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com.  

Forward-looking Statements Statements
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... BETHESDA, Md. , May 1, 2015  Northwest ... biotechnology company developing DCVax® personalized immune therapies for solid ... on the $28.5 million second tranche of a $40 ... ("Woodford"). Woodford first invested $25 million in ... 2015, Woodford entered into an agreement with the Company ...
(Date:5/1/2015)... , May 1, 2015 /CNW/ - Softchoice, a leading North ... it is the proud recipient of two Cisco® Partner Summit ... Partner of the Year and Security Partner of the Year ... conference taking place this week in Montreal ... one, but two Cisco partner awards at this year,s conference," ...
(Date:5/1/2015)... 2015 According to a ... (Equipment, Consumables), by Type (Monoclonal, Polyclonal), by Technology ... Institutes) - Analysis & Global Forecast to 2019", ... Antibody Production Market for the forecast period of ... reach $2.572 Billion by 2019 from $1.425 Billion ...
(Date:4/30/2015)... SAN DIEGO , April 30, 2015   ... drugs, announced today an update on its Ebola antiviral ... of Tamir,s leading candidates, TMR004, is currently being evaluated ... frontline of the battle against Ebola. During the first ... Voice And Leadership Meeting To Accelerate The Evaluation of ...
Breaking Biology Technology:NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4
... world,s largest library of Jatropha genetic materialSAN DIEGO, Feb. ... of energy, biotechnology and agribusiness veterans today announced the ... CA-based plant oil company specializing in the development of ... Kirk Haney , President and Chief Executive Officer, introduced ...
... Feb. 2 /PRNewswire-FirstCall/ - BioSyntech, Inc. (TSX: BSY), ... medicine, today announced that it has completed enrolment ... repair device, BST-CarGel(R). The Company achieved its planned ... trial. , "We are grateful to the distinguished ...
... HOLLYWOOD, Calif., Feb. 2 IPC The Hospitalist Company, Inc. (Nasdaq: IPCM ), a leading national physician ... held in New York, NY. , , ... Speakers: Adam Singer, ... ...
Cached Biology Technology:Energy, Biotechnology and Agribusiness Veterans Form SG Biofuels to Develop Jatropha as Low-Cost, Sustainable Oil 2BioSyntech Achieves Enrolment Goal for Pivotal Trial of BST-CarGel(R), its Cartilage Repair Device 2BioSyntech Achieves Enrolment Goal for Pivotal Trial of BST-CarGel(R), its Cartilage Repair Device 3IPC The Hospitalist Company, Inc. to Present at UBS 2009 Global Healthcare Services Conference 2
(Date:4/1/2015)...   Medisafe ™, the leading global medication management ... and Android smartphones and tablets, announces ... platform to allow patients to track and correlate their ... patients will be able to visualize in real-time how ... such as glucose levels and blood pressure. ...
(Date:3/26/2015)... -- The Granite Club, Canada,s ... today announced it has implemented a state-of-the-art access and ... members and staff, while restricting access to authorized users ... FST,s IMID Access system because it has the perfect ... staff, in addition to unparalleled security," said James ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... Family Research and Education Center was awarded a $330,124 grant ... learn through their own creative play in natural playgrounds. The ... will support researchers as they observe young children exploring the ... Nature Center as well as the PlayScape that is currently ...
... serious health risks associated with the diets of indigenous ... primary food source to a decrease in the power ... Publishing,s journal Environmental Research Letters , the study ... contaminants, such as mercury, in the subsistence diets that ...
... visible light after being exposed to sunlight are commonplace and ... stickers. But until now, scientists have had little success creating ... of the spectrum that only can be seen with the ... in the early online edition of the journal Nature ...
Cached Biology News:UC Arlitt Center awarded NSF grant to research learning at PlayScapes 2Huskies lend insight into mercury risk 2UGA scientists invent long-lasting, near infrared-emitting material 2
... g of monoclonal antibody reactive against the complex ... are highest in growing cultured cells. SURF1 is ... which is thought to participate in the folding ... this subunit. Mutations of SURF1, particularly ones that ...
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Tropomyosin 4 [Tm4]...
Biology Products: